Rezultati pretraživanja
  1. prije 7 sati

    Today is World Cancer Day. Share your reasons for specializing in treating genitourinary cancers by leaving a comment below.

    1 reply 5 proslijeđenih tweetova 5 korisnika označava da im se sviđa
  2. 2. velj

    Patients w/ cT3 and/or pT3N0M0 harbor worse 3-5yr CSS & Bladder Rec Free Survival when RNU is performed laparoscopically compared to Open Read more 👇

    13 proslijeđenih tweetova 25 korisnika označava da im se sviđa
  3. 30. sij

    In this webcast, 3 real-life clinical cases were discussed on the contemporary key topics in (PN) from a surgical point of view. 👇

    5 proslijeđenih tweetova 11 korisnika označava da im se sviđa
  4. 27. sij

    Interesting data as this concept seems to be a recurring question and a focus of continued in especially

    Primary tumor resection in metastatic asymptomatic colon cancer does not improve overall survival
    1 reply 1 proslijeđeni tweet 7 korisnika označava da im se sviđa
  5. 14. sij

    that are of the genitourinary system, encompassing the organs of the reproductive & urinary systems? This includes the prostate, kidney, bladder, testicles, penis & adrenal gland cancers. RT to show your support of those affected by

    1 proslijeđeni tweet 1 korisnik označava da mu se sviđa
  6. 26. pro 2019.

    thank you for invitation! A lot of interesting topics and advancements made the past 2 years. Always glad to share and discuss in this forum.

    In this video update, Dr. Nazanin Fallah-Rad presents the evidence and future directions for immune-therapy in GU Cancers:
    1 proslijeđeni tweet 3 korisnika označavaju da im se sviđa
  7. 19. lis 2019.

    GU Oncology Symposium Dr from talking about management of small renal mass, organ confined PC, BCG refractory non-invasive BC – mjesto: Saint Agnes Medical Center

    2 proslijeđena tweeta 10 korisnika označava da im se sviđa
  8. 10. ruj 2019.

    UNC A031702 startup today. Thanks to for designing this study for our patients with led by UNC PI . leading the way for patients with .

    6 proslijeđenih tweetova 9 korisnika označava da im se sviđa
  9. 7. kol 2019.

    Our latest ed pick: infection associated with worse outcomes in older individuals. Click through to read the news story. Research published in .

    2 proslijeđena tweeta 2 korisnika označavaju da im se sviđa
  10. 6. kol 2019.

    News: infection associated with worse outcomes, report Anna Coghill (of ) & colleagues. Full article in .

    2 proslijeđena tweeta
  11. 2. kol 2019.

    approvalsWatch: becomes the third nonsteroidal antiandrogen to be approved by the for men with nonmetastatic castration-resistant .

    2 proslijeđena tweeta 1 korisnik označava da mu se sviđa
  12. 28. srp 2019.

    Dr Narayan of started the day with updates in from at the ASCO Direct Highlights Philadelphia.

    1 proslijeđeni tweet 2 korisnika označavaju da im se sviđa
  13. 13. lip 2019.

    Drs Choueiri & El Bakouny from said, "“Overall, TITAN and ENZAMET are practice-changing phase III randomized, controlled trials..." in their discussion on the top abstracts for at .

    2 proslijeđena tweeta 4 korisnika označavaju da im se sviđa
  14. 31. svi 2019.

    VIDEO: The importance of education w/ of : @Uro_Onc

    5 proslijeđenih tweetova 6 korisnika označava da im se sviđa
  15. 30. svi 2019.

    VIDEO: 177Lu-PSMA-617 radionuclide therapy in mCRPC w/ of : @Uro_Onc

    2 proslijeđena tweeta 7 korisnika označava da im se sviđa
  16. 29. svi 2019.

    VIDEO: Looking to the future of treatment w/ Michael Atkins of : @Uro_Onc

  17. 1. ožu 2019.

    Dr. William Kim reviews the importance of in Clinical Studies planned in using M7824 which targets both & TGFb

    7 proslijeđenih tweetova 20 korisnika označava da im se sviđa
  18. 27. velj 2019.
    Odgovor korisnicima

    I study immune infiltration and organization in , with a focus on the T-cell response in humans and in mouse models. This work has especially utilized some neat imaging tech! So, I'll go with..

    1 proslijeđeni tweet 10 korisnika označava da im se sviđa
  19. 27. velj 2019.

    Kicking off conference with our Tumor Board discussing difficult and advanced cases of with our colleagues in radiology, pathology, oncology, and rad onc.

    2 korisnika označavaju da im se sviđa
  20. 18. velj 2019.

    Dr. Balar addressed a challenge in using of immunotherapy in early-stage bladder cancer.

Nema rezultata.

Čini se da učitavanje traje već neko vrijeme.

Twitter je možda preopterećen ili ima kratkotrajnih poteškoća u radu. Pokušajte ponovno ili potražite dodatne informacije u odjeljku Status Twittera.